Research prototype, not medical advice.

10 — Altered intercellular communication

"Integrative" hallmark (López-Otín et al., Cell 2023, 10.1016/j.cell.2022.11.001). It describes how the messages exchanged between cells, tissues and organs go wrong with age, spreading aging from one part of the body to another.

1. Definition

Cells talk to each other constantly: hormones, growth factors, inflammatory molecules, vesicles, contacts with the matrix that surrounds them. With age, this dialogue becomes scrambled. The blood of an old organism carries more harmful signals and fewer protective ones, and the "scaffolding" of tissues (extracellular matrix) stiffens.

In plain terms: imagine a company where internal messages are distorted and rumours (inflammation) spread faster than good instructions. Even if each employee stays competent, the whole works badly.

2. Mechanisms and sources

2.1 The blood environment (systemic factors)

The founding experiment is heterochronic parabiosis: the circulations of a young mouse and an old mouse are surgically joined.

In plain terms: removing the "bad messages" from old blood seems to matter at least as much as adding young "good messages".

2.2 The control centres (neuroendocrine axes)

The hypothalamus, the brain region that steers hormones and metabolism, acts as a conductor of aging. Local inflammation there (IKK-β/NF-κB pathway) accelerates systemic aging in mice, and blocking it extends life (Zhang 2013, 10.1038/nature12143). Hypothalamic stem cells slow aging partly through microRNAs carried in exosomes (small vesicles) (Zhang 2017, 10.1038/nature23282).

2.3 The secretion of senescent cells (SASP)

Senescent cells (see 08) secrete an inflammatory cocktail (SASP) that makes their neighbours senescent: this is paracrine senescence, orchestrated by the inflammasome (Acosta 2013, 10.1038/ncb2784). Transplanting a few senescent cells into a young mouse is enough to cause lasting physical dysfunction (Xu 2018, 10.1038/s41591-018-0092-9).

2.4 The extracellular matrix

The matrix is the network of proteins (collagen, elastin) that surrounds cells and transmits mechanical signals to them. With age, it stiffens (cross-links, glycation) and becomes disorganised. In the worm C. elegans, collagen remodelling is required for the longevity induced by the insulin/IGF-1 pathway (Ewald 2014, 10.1038/nature14021). In humans, causal data are lacking: the link is mostly correlational (fibrosis, arterial stiffness).

3. Symptoms and clinical manifestations

4. Interactions with the other hallmarks

5. Existing or investigational remedies

InterventionTargetLevel of evidenceKey resultSource
Heterochronic parabiosisBlood environmentPreclinical (mice)Rejuvenation of muscle, liver, brainConboy 2005 ; Villeda 2011
Young plasma injectionBlood factorsPreclinical (mice)Improved memory and synaptic plasticityVilleda 2014
Dilution of old plasma (saline-albumin)Harmful blood factorsPreclinical (mice)Several tissues rejuvenatedMehdipour 2020
Plasma exchange with albumin (AMBAR)Moderate Alzheimer's diseaseHuman phase IIb/III trialSlower decline on some endpoints, mixed resultsBoada 2020
Young plasma infusion (PLASMA)Alzheimer's diseaseHuman phase I trialSafe and feasible, no efficacy shown (small sample)Sha 2019
Cord plasma proteins (TIMP2)HippocampusPreclinical (mice)Improved hippocampal functionCastellano 2017
GPLD1 (exercise factor)NeurogenesisPreclinical (mice)Improved cognition in old animalsHorowitz 2020
Inhibition of hypothalamic NF-κBHypothalamusPreclinical (mice)Slower aging, longer lifeZhang 2013
Senolytics (dasatinib + quercetin)Senescent cells / SASPPreclinical (mice); first human trials (see 08, 11)Improved physical function and survivalXu 2018
Physical exerciseCirculating factors, hormonesRecommended (not a formal "anti-aging" indication)Transfers benefits through the blood in miceHorowitz 2020

No intervention on intercellular communication is approved against aging. Commercial clinics have sold young plasma infusions with no proof of efficacy; the FDA issued a warning on 19 February 2019: no proven clinical benefit, real risks (FDA 2019).

6. Open questions

7. References